QRG Capital Management Inc. Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• QRG Capital Management increased its stake in Vertex by 16.2% in Q4 to 18,396 shares, valued at approximately $8.34 million.
• Q1 results beat EPS — Vertex reported $4.47 EPS vs. $4.24 expected and showed product-driven revenue growth, while reiterating full‑year 2026 revenue guidance of about $13.0–$13.1 billion and carrying a consensus "Moderate Buy" with a ~$554.83 price target.
• Insider selling has been significant recently, with insiders disposing of 81,853 shares (~$38.48 million) in the past 90 days, including trades executed under 10b5‑1 plans, which may weigh on near‑term sentiment despite analyst support.

QRG Capital Management Inc. increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 16.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 18,396 shares of the pharmaceutical company's stock after acquiring an additional 2,563 shares during the period. QRG Capital Management Inc.'s holdings in Vertex Pharmaceuticals were worth $8,340,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Colonial Trust Co SC raised its stake in shares of Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 38 shares during the period. Eagle Bay Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth $29,000. Ares Financial Consulting LLC purchased a new position in shares of Vertex Pharmaceuticals in the fourth quarter valued at $33,000. Financial Network Wealth Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 50.9% in the third quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company's stock valued at $34,000 after purchasing an additional 29 shares during the period. Finally, Archer Investment Corp grew its holdings in Vertex Pharmaceuticals by 89.7% during the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company's stock valued at $34,000 after purchasing an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Analyst Ratings Changes

VRTX has been the topic of several analyst reports. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an "overweight" rating in a research note on Tuesday. Royal Bank Of Canada upped their price objective on shares of Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an "outperform" rating in a research report on Tuesday. Truist Financial upgraded Vertex Pharmaceuticals to a "strong-buy" rating in a research note on Monday, April 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $590.00 target price on shares of Vertex Pharmaceuticals in a research report on Friday, February 13th. Finally, Sanford C. Bernstein cut their price target on Vertex Pharmaceuticals from $577.00 to $572.00 and set an "outperform" rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $554.83.

Insiders Place Their Bets

In related news, Director Sangeeta N. Bhatia sold 318 shares of the company's stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $423.73, for a total transaction of $134,746.14. Following the sale, the director directly owned 4,924 shares of the company's stock, valued at approximately $2,086,446.52. This represents a 6.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark E. Bunnage sold 620 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $301,537.00. Following the transaction, the executive vice president owned 7,284 shares in the company, valued at $3,542,573.40. This trade represents a 7.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 81,853 shares of company stock worth $38,479,135. Corporate insiders own 0.20% of the company's stock.

Key Headlines Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat on EPS and showed revenue growth driven by product sales; management highlighted broad portfolio strength and pipeline progress, supporting longer‑term growth thesis. Business Wire: Vertex Reports First Quarter 2026 Financial Results
• Positive Sentiment: Sales of new CF therapies and other recently launched products accelerated, contributing materially to product revenue growth and suggesting multiple near‑term commercial growth engines. Reuters: Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Neutral Sentiment: Vertex reiterated full‑year 2026 revenue guidance (~$13.0B–$13.1B), roughly in line with consensus — supportive for guidance stability but not a clear upside catalyst. Investor Slide Deck / Press Release (Q1 2026)
• Neutral Sentiment: Analysts revised models and price targets after the Q1 release — many maintained Outperform/Buy views but trimmed targets, reflecting mixed near‑term readings despite constructive longer‑term views. Benzinga: These Analysts Revise Their Forecasts On Vertex After Q1 Earnings
• Negative Sentiment: Insider selling was reported this week (EVP Joy Liu sold 1,104 shares; director Sangeeta Bhatia sold 318 shares). Trades were executed under 10b5‑1 plans, but active insider sales can weigh on sentiment. SEC Form 4 (Joy Liu) SEC Form 4 (Sangeeta Bhatia)
• Negative Sentiment: Shares dipped after the mixed report (EPS/revenue beats but some metrics and commentary left investors cautious), prompting near‑term profit‑taking and PT trims. Yahoo Finance: Vertex Dips On Mixed First‑Quarter Report

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $424.36 on Wednesday. The stock has a market capitalization of $107.94 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 1.87 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $507.92. The company's 50-day simple moving average is $452.77 and its 200-day simple moving average is $449.59.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 24.41% and a net margin of 35.51%.The firm had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. During the same period in the previous year, the company earned $4.06 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 8.3% on a year-over-year basis. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.